Shire (NASDAQ:SHPG) had its target price trimmed by Royal Bank of Canada to $181.00 in a research note published on Friday. The brokerage currently has an outperform rating on the biopharmaceutical company’s stock.
Other equities research analysts have also issued research reports about the stock. FBR & Co started coverage on shares of Shire in a report on Thursday, October 19th. They issued a buy rating and a $201.00 price objective for the company. Cantor Fitzgerald reaffirmed a buy rating and set a $222.00 target price on shares of Shire in a research note on Friday, October 27th. ValuEngine raised shares of Shire from a hold rating to a buy rating in a research note on Thursday, October 26th. Liberum Capital raised shares of Shire from a hold rating to a buy rating in a research note on Tuesday, November 14th. Finally, Cowen set a $225.00 target price on shares of Shire and gave the stock a buy rating in a research note on Sunday, October 29th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and eleven have assigned a buy rating to the stock. The stock has a consensus rating of Buy and a consensus target price of $209.23.
Shares of Shire (SHPG) opened at $134.06 on Friday. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.98 and a quick ratio of 0.52. Shire has a 1-year low of $123.73 and a 1-year high of $192.15. The stock has a market cap of $40,900.00, a PE ratio of 6.12, a P/E/G ratio of 0.75 and a beta of 1.41.
The firm also recently disclosed a semiannual dividend, which will be paid on Tuesday, April 24th. Stockholders of record on Friday, March 9th will be paid a $0.8937 dividend. This is a positive change from Shire’s previous semiannual dividend of $0.15. The ex-dividend date of this dividend is Thursday, March 8th. This represents a dividend yield of 1.33%. Shire’s dividend payout ratio (DPR) is presently 4.20%.
Several hedge funds and other institutional investors have recently bought and sold shares of SHPG. SeaCrest Wealth Management LLC purchased a new position in shares of Shire in the fourth quarter valued at approximately $107,000. Avestar Capital LLC purchased a new position in shares of Shire in the fourth quarter valued at approximately $116,000. Amica Retiree Medical Trust purchased a new position in shares of Shire in the fourth quarter valued at approximately $120,000. BB&T Investment Services Inc. boosted its stake in shares of Shire by 1,672.3% in the third quarter. BB&T Investment Services Inc. now owns 833 shares of the biopharmaceutical company’s stock valued at $127,000 after purchasing an additional 786 shares during the period. Finally, Steward Partners Investment Advisory LLC purchased a new position in shares of Shire in the third quarter valued at approximately $159,000. 20.92% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: “Royal Bank of Canada Lowers Shire (SHPG) Price Target to $181.00” was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://www.chaffeybreeze.com/2018/02/20/royal-bank-of-canada-lowers-shire-shpg-price-target-to-181-00.html.
Shire Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.